Supernus Pharmaceuticals Inc (NASDAQ:SUPN) Expected to Post Quarterly Sales of $109.26 Million

Brokerages forecast that Supernus Pharmaceuticals Inc (NASDAQ:SUPN) will post sales of $109.26 million for the current quarter, Zacks reports. Four analysts have provided estimates for Supernus Pharmaceuticals’ earnings. The highest sales estimate is $111.45 million and the lowest is $106.20 million. Supernus Pharmaceuticals posted sales of $103.00 million in the same quarter last year, which suggests a positive year-over-year growth rate of 6.1%. The firm is scheduled to issue its next earnings report on Tuesday, November 5th.

On average, analysts expect that Supernus Pharmaceuticals will report full-year sales of $414.98 million for the current financial year, with estimates ranging from $410.90 million to $419.58 million. For the next fiscal year, analysts anticipate that the company will post sales of $451.75 million, with estimates ranging from $435.77 million to $466.80 million. Zacks’ sales calculations are an average based on a survey of sell-side analysts that cover Supernus Pharmaceuticals.

Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its quarterly earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported $0.61 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.56 by $0.05. Supernus Pharmaceuticals had a net margin of 25.66% and a return on equity of 22.36%. The company had revenue of $104.70 million during the quarter, compared to the consensus estimate of $109.67 million. During the same period last year, the firm earned $0.57 EPS. The company’s revenue for the quarter was up 5.2% on a year-over-year basis.

SUPN has been the subject of a number of research reports. BidaskClub downgraded shares of Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, October 9th. ValuEngine upgraded shares of Supernus Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, October 2nd. Cowen set a $50.00 price target on shares of Supernus Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, August 7th. Stifel Nicolaus set a $55.00 price target on shares of Supernus Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, August 7th. Finally, TheStreet downgraded shares of Supernus Pharmaceuticals from a “b-” rating to a “c+” rating in a research report on Thursday, August 29th. One analyst has rated the stock with a sell rating, three have issued a hold rating and six have given a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $53.38.

SUPN stock opened at $26.60 on Friday. The firm has a 50 day moving average of $27.19 and a 200-day moving average of $31.10. Supernus Pharmaceuticals has a 12-month low of $24.77 and a 12-month high of $49.25. The company has a current ratio of 2.72, a quick ratio of 2.53 and a debt-to-equity ratio of 0.70. The company has a market cap of $1.39 billion, a price-to-earnings ratio of 12.98, a PEG ratio of 0.93 and a beta of 1.61.

In other Supernus Pharmaceuticals news, CEO Jack A. Khattar acquired 7,200 shares of the company’s stock in a transaction dated Friday, August 23rd. The stock was acquired at an average cost of $26.39 per share, with a total value of $190,008.00. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Company insiders own 6.57% of the company’s stock.

Several institutional investors and hedge funds have recently modified their holdings of the company. Vanguard Group Inc. increased its stake in shares of Supernus Pharmaceuticals by 0.9% during the 2nd quarter. Vanguard Group Inc. now owns 5,345,217 shares of the specialty pharmaceutical company’s stock worth $176,873,000 after purchasing an additional 49,676 shares in the last quarter. Rice Hall James & Associates LLC grew its stake in Supernus Pharmaceuticals by 35.1% in the 2nd quarter. Rice Hall James & Associates LLC now owns 1,351,286 shares of the specialty pharmaceutical company’s stock worth $44,714,000 after acquiring an additional 350,905 shares during the period. Macquarie Group Ltd. grew its stake in Supernus Pharmaceuticals by 8.5% in the 2nd quarter. Macquarie Group Ltd. now owns 1,079,001 shares of the specialty pharmaceutical company’s stock worth $35,705,000 after acquiring an additional 84,846 shares during the period. Neumeier Poma Investment Counsel LLC grew its stake in Supernus Pharmaceuticals by 1.1% in the 2nd quarter. Neumeier Poma Investment Counsel LLC now owns 957,401 shares of the specialty pharmaceutical company’s stock worth $31,680,000 after acquiring an additional 10,170 shares during the period. Finally, Provident Investment Management Inc. grew its stake in Supernus Pharmaceuticals by 13.8% in the 2nd quarter. Provident Investment Management Inc. now owns 726,333 shares of the specialty pharmaceutical company’s stock worth $24,034,000 after acquiring an additional 88,099 shares during the period. 99.14% of the stock is owned by institutional investors and hedge funds.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy and migraine.

See Also: Trading Ex-Dividend Strategy

Get a free copy of the Zacks research report on Supernus Pharmaceuticals (SUPN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.